Dynamic42 GmbH develops human, three-dimensional physiological organ models in a biochip. We are a contract research organization, and we are testing new drugs as well as novel dosage forms of drugs (i.e. nanoparticles). In addition, we are developing customized biochip-based assays and organ models (disease and infection models) for further studies.
Organ-on-Chip Contract Research Services
You can use our services for toxicology screenings, lead identification and optimization as well as in vitro model development. Our unique immune-competent organ models enable you to gain deeper understanding of human cellular biology in health and disease. It can help you to strengthen your pre-clinical data set, to perform target validation, to investigate molecular mechanisms and to prioritize further developments.
Our services
/ 3D cell culture
/ Assay development
/ Cell culture
/ Cytokine release assay
/ Hematoxylin & Eosin (H&E) Staining
/ Immunostaining
/ In Vitro Assay Development
/ Inflammation Assays
/ Organotypic Culture
/ Organs-On-Chips
/ Oxidative Burst
/ Phenotype Assays and Reactive Species Assays
Dynamic42 Organ-on-Chip models
We offer services around our different Organ-on-Chip models:
Why work with us?
Comprehensive, fast, biologically relevant – all from a single source
The Dynamic42 services are based on its unique technology to integrate tissue-resident and circulating immune cell populations into human Organ-on-Chip models.
We offer you our immuno-competent Organ-on-Chip platform to perform tailored fee-for-service studies. Our motivated, well trained scientific team individually plans the scope of your study together with you, sets milestones and criteria for go and no-go decisions.
Step by step!
Together we build up study plans to specifically address your scientific needs. This includes small pilot and feasibility studies, regular screenings, and extensive long-term projects.
Modularity
We identify the optimal biological Organ-on-Chip setup for you. The great potential of the technology lies in the fact that individual biological and technical components can be easily modified. To achieve your goals, we make use of one principle: a modular cellular construction kit.
Unique biochip design
We provide services to design and fabricate customized biochips!
Some applications or scientific questions need adjustments in biochip geometry or biochip materials. Our engineers provide technical expertise and support.
We use state-of-the-art manufacturing techniques to provide fast and accurate solutions with high quality.
More about biochips
Examples of customer projects
Three-organ-chip – liver, intestine, placenta
Pilot project, supported by esqLABS, Dynamic42 GmbH, Placenta Lab of Jena University Hospital, and Bayer’s Consumer Health Division which aims to generate clinically relevant data, a key step in evaluating new drug candidates in preclinical research. This project focuses on evaluating whether small molecules can cross the blood-placenta-barrier in pregnant women, an understudied population due to challenges in conducting clinical research. The platform will consist of a microphysiological system (so called “organ-on-chip”) representing the main human tissues involved in drug disposition (liver, intestine, placenta) as well as a pumping system to circulate cell culture media among the tissues.
More about this project
Spheroid-on-chip – combining cell-based organoids with blood vessel tissue
We are developing a three-channel micro cavity-equipped microfluidic biochip in collaboration with the working group of Prof. Nicole Teusch from the Heinrich Heine University Düsseldorf to generate patient-derived pancreatic cancer spheroid-on-a-chip models for screening novel therapeutic approaches.
This biochip enables the cultivation of complex, three-dimensional tissue cultures and opens up the possibility of cultivating spheroids and stem cell-based organoids in one chip platform and to combine them with other tissue components, such as blood vessel tissue. In this project, a 3D pancreatic adenocarcinoma model was developed from pancreatic cells for preclinical testing to investigate therapeutic options.
More about this project
Innovative model systems for the evaluation of immunomodulatory therapeutics
While preclinical studies have so far mainly investigated the basic toxicity of a new therapeutic agent on the (healthy) immune system, there is a lack of non-clinical models that accurately capture the individual interactions of the human immune system in the pathogenic state.
The EU consortium inSAVAR (Immune Safety Avatar: nonclinical mimicking of the immune system effects of immunomodulatory therapies) addresses this shortcoming with new concepts for testing immunomodulatory therapies. The aim is to improve existing and develop new model systems in order to:
/ Identify undesirable side effects of new therapies on the immune system
/ Develop new biomarkers for the diagnosis and prognosis of immune-mediated pharmacologies and toxicities
/ Explore toxicity mechanisms and the potential for their mitigation through therapeutic interventions in more detail.
/ The project thus aims to lay the foundations for new, Europe-wide standards in drug development.
The interdisciplinary consortium imSAVAR comprises 28 international partners from 11 nations under the scientific coordination of the Fraunhofer Institute for Cell Therapy and Immunology IZI (Leipzig, Germany) and Novartis (Basel, Switzerland).
More about this project
Antifungal therapy approaches with nanoparticle-based targeting of drugs
This research projects is embedded within the Athana alliance which brings together companies and research institutions from Thuringia that are leaders in pharmaceutical biotechnology and the infection and clinical research sector. The aim of this project is to develop functionalised nanoparticles that deliver drugs precisely to where they are needed in the body. The alliance aims to establish versatile platform technology for the use of target-guided nanoparticles for the treatment of infectious diseases. By targeting disease with medicine via functionalised nanoparticles, it will be possible to increase efficacy and reduce side effects due to the smaller quantities of drugs involved. With the help of a modular construction system, the innovative platform will permit the flexible production of therapeutic nanoparticles with different types of functionalities for the treatment of infectious diseases.
More about this project
Didn’t find what you were looking for?
If your research needs don’t fit with one of our standard services, let us know. We’ve got expert scientists who can work with you to create a custom collaboration project for your application of interest. Each of our organ-on-chip models and applications can be tailored to meet your research requirements. Just get in touch to let us know what you’re looking for, and our team will work with you to determine how we can help.